Michael Callahan’s career began in USAID and in the bioweapons labs of the former Soviet Union, advancing the agenda of the global bioweapons and pharmaceutical cartels. He would take what he learned there to execute a massive expansion of DARPA’s biodefense portfolio and today finds himself squarely in the center of the origins of the coronavirus pandemic.

Dr. Michael Callahan was given a leave of absence from his senior executive role at United Therapeutics (UTHR) in the wake of the COVID-19 outbreak in Wuhan, China; sent there to assist colleagues handling mass infections of the novel coronavirus under his joint appointment at a Chinese sister hospital of the Massachusetts General Hospital/Harvard Medical School, where he has maintained a faculty appointment since 2005.

Soon, Callahan would be pouring through thousands of case studies emerging from the epicenter of the outbreak in Wuhan, examining patients in Singapore and briefing U.S. officials on the location of the next likely outbreak, according to NatGeo. The doctor marveled at the “magnificent infectivity” of the disease, which sits “like a little silent smart bomb in your community”.